White matter changes in familial Alzheimer's disease

Journal of Internal Medicine

Volumn 278, Issue 2, 2015, Pages 211-218

  Li, X ^a   Westman, E ^a   Stahlbom A K ^a,b   Thordardottir, S ^a,b   Almkvist, O ^a,c   Blennow, K ^d   Wahlund, Lars Olof ^a   Graff, C ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cerebrospinal fluid biomarkers; diffusion tensor imaging; familial Alzheimer's disease; mutation carriers; white matter changes

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; BRAIN SIZE; CEREBROSPINAL FLUID; CINGULUM (BRAIN); CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; FAMILIAL ALZHEIMER DISEASE; FAMILIAL DISEASE; FEMALE; FORCEPS MAJOR; FRACTIONAL ANISOTROPY; GENE MUTATION; GRAY MATTER; HETEROZYGOTE; HUMAN; INFERIOR LONGITUDINAL FASCICULUS; LEFT HEMISPHERE; MALE; MIDDLE AGED; PRIORITY JOURNAL; SUPERIOR LONGITUDINAL FASCICULUS; VOXEL BASED MORPHOMETRY; WHITE MATTER; DIFFUSION WEIGHTED IMAGING; GENETICS; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PROCEDURES;

ADULT; ALZHEIMER DISEASE; DIFFUSION MAGNETIC RESONANCE IMAGING; DIFFUSION TENSOR IMAGING; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; WHITE MATTER;

EID: 84942423672     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12352     Document Type: Article

References (35)

1. Sjogren T, Sjogren H, Linddgren A. Morbus Alzheimer and morbus Pick; a genetic, clinical and patho-anatomical study. Acta Neurol Scand Suppl 1952; 82: 1–152.
2. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010; 68: 270–81.
3. Ridha BH, Barnes J, Bartlett JW et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 2006; 5: 828–34.
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353–6.
5. Anand R, Kaushal A, Wani WY, Gill KD. Road to Alzheimer's disease: the pathomechanism underlying. Pathobiology 2012; 79: 55–71.
6. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM. Presymptomatic hippocampal atrophy in Alzheimer's disease A longitudinal MRI study. Brain 1996; 119: 2001–7.
7. Cash DM, Ridgway GR, Liang Y et al. The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. Neurology 2013; 81: 1425–33.
8. Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cummings JL. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical “disconnection” in aging and Alzheimer's disease. Neurobiol Aging 2004; 25: 843–51.
9. Sexton CE, Kalu UG, Filippini N, Mackay CE, Ebmeier KP. A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2011; 32: 2322.e5–18.
10. Ringman JM, O'Neill J, Geschwind D et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain 2007; 130: 1767–76.
11. Ryan NS, Keihaninejad S, Shakespeare TJ et al. Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. Brain 2013; 136: 1399–414.
12. Klunk WE, Price JC, Mathis CA et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007; 27: 6174–84.
13. Ringman JM, Younkin SG, Pratico D et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008; 71: 85–92.
14. Schöll M, Wall A, Thordardottir S et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012; 79: 229–36.
15. Bateman RJ, Xiong C, Benzinger TLS et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795–804.
16. Li X, Li T-Q, Andreasen N, Wiberg MK, Westman E, Wahlund L-O. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease. J Intern Med 2014; 275: 418–27.
17. Mullan M, Crawford F, Axelman K. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992; 1: 345–7.
18. Nilsberth C, Westlind-danielsson A, Eckman CB et al. The “Arctic” APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat Neurosci 2001; 4: 18–23.
19. Clark R, Hutton M, Fuldner R, Froelich S, Karran C. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Alzheimer's Disease Collaborative Group. Nat Genet 1995; 11: 219–22.
20. Keller L, Welander H, Chiang H-H et al. The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: clinical report and quantification of Aβ in different brain regions. Eur J Hum Genet 2010; 18: 1202–8.
21. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98.
22. Zetterberg H, Andreasson U, Hansson O et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 2008; 65: 1102–7.
23. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995; 26: 231–45.
24. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Andreasen N, Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285: 49–52.
25. Winblad B, Palmer K, Kivipelto M et al. Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240–6.
26. Simmons A, Westman E, Muehlboeck S et al. MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci 2009; 1180: 47–55.
27. Simmons A, Westman E, Muehlboeck S et al. The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry 2011; 26: 75–82.
28. Wu L, Rosa-neto P, Hsiung GR et al. Early-Onset Familial Alzheimer ‘ s Disease (EOFAD). Can J Neurol Sci 2012; 39: 436–45.
29. Schott JM, Fox NC, Frost C et al. Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol 2003; 53: 181–8.
30. Fellgiebel A, Wille P, Müller MJ et al. Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement Geriatr Cogn Disord 2004; 18: 101–8.
31. Loewenstein DA, Barker WW, Chang JY et al. Predominant left hemisphere metabolic dysfunction in dementia. Arch Neurol 1989; 46: 146–52.
32. Buckner RL, Snyder AZ, Shannon BJ et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709–17.
33. Sjöbeck M, Englund E. Glial levels determine severity of white matter disease in Alzheimer ‘ s disease : a neuropathological study of glial changes. Neuropathol Appl Neurobiol 2003; 29: 159–69.
34. Fernando MS, O'Brien JT, Perry RH et al. Comparison of the pathology of cerebral white matter with post-mortem magnetic resonance imaging (MRI) in the elderly brain. Neuropathol Appl Neurobiol 2004; 30: 385–95.
35. Sexton CE, Mackay CE, Lonie JA et al. MRI correlates of episodic memory in Alzheimer's disease, mild cognitive impairment, and healthy aging. Psychiatry Res 2010; 184: 57–62.